Northland Securities analyst Suraj Kalia maintained a Buy rating on Strata Skin Sciences Inc (SSKN) today and set a price target of $7. The company’s shares opened today at $2.85.
Kalia said:
“We note that the rec. revs biz is predominantly from the U.S., and has been trending nicely upward (Q1 = $6,000; Q2 = $6,500; Q3 = $7,000; Q4 = $8,063). A key premise of our initiation thesis on Strata was the simple logic that a return to utilization rates of $12,000/unit would roughly double overall revs. To that end, Strata’s turnaround strategy seems to be yielding fruit.”
According to TipRanks.com, Kalia is a 5-star analyst with an average return of 10.9% and a 58.0% success rate. Kalia covers the Healthcare sector, focusing on stocks such as Tactile Systems Technology, Varex Imaging Corporation, and Obalon Therapeutics Inc.
Currently, the analyst consensus on Strata Skin Sciences Inc is a Moderate Buy with an average price target of $7.
See today’s analyst top recommended stocks >>
Based on Strata Skin Sciences Inc’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $290K. In comparison, last year the company had a GAAP net loss of $2.22 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
STRATA Skin Sciences, Inc. is a medical technology company, which engages in the design, development, and commercializing of non-invasive tools to provide additional information to dermatologists during melanoma skin examinations.
